Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02489539 · ClinicalTrials.gov registry record · NA

Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms

A NA study of Aortic Aneurysm, Abdominal, sponsored by W.L.Gore & Associates.

Active
Registry status
NA
Development phase
175
Enrollment target
20
Study locations

NCT02489539 is a NA study of Aortic Aneurysm, Abdominal that is active but no longer recruiting, run by W.L.Gore & Associates. The registered enrollment target is 175 participants, above the 133-participant average among 8 other Aortic Aneurysm, Abdominal trials with a reported enrollment target (32% higher). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02489539, a NA study of Aortic Aneurysm, Abdominal, is active but no longer recruiting, sponsored by W.L.Gore & Associates.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
175 participants
Enrollment target
20
Study locations

Study Summary

The purpose of the study is to assess the safety and effectiveness of the GORE® EXCLUDER® Conformable AAA Endoprosthesis to treat an infrarenal aneurysm located in the abdominal aorta. Performance of the GORE® EXCLUDER® Conformable AAA Endoprosthesis will be judged by separate performance goals.

Conditions Studied

Interventions

  • DEVICE GORE® EXCLUDER® Conformable AAA Endoprosthesis

Study Locations (20)

Florida

  • River City Clinical Research - Jacksonville
  • Baptist Cardiac and Vascular Institute - Miami
  • Florida Hospital - Orlando
  • Sarasota Vascular Specialists - Sarasota

Minnesota

  • Essentia Institute of Rural Health - Duluth
  • Minneapolis Heart Institute Foundation - Abbott Northwestern Hospital - Minneapolis
  • Minneapolis Radiology and Vascular Research Foundation - Plymouth
  • Mayo Clinic - Rochester - Rochester

California

  • University of Southern California - Los Angeles
  • Leland Stanford Junior University - Stanford

Georgia

  • Emory University - Atlanta
  • Vascular Surgical Associates, PC - Marietta

Illinois

  • Loyola University - Chicago - Maywood
  • Southern Illinois University - Springfield

Michigan

  • University of Michigan - Ann Arbor
  • Spectrum Health System - Grand Rapids

Alabama

  • University of Alabama at Birmingham - Birmingham

Arizona

  • Mayo Clinic Arizona - Phoenix

Trial Details

FieldValue
Enrollment Target 175 participants
Start Date 2017-12-19
Est. Completion 2027-12-31
Phase NA

Sponsor

W.L.Gore & Associates

53 total trials

What the Registry Record Tells You About NCT02489539

The ClinicalTrials.gov registry entry for NCT02489539 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 133-participant average among 8 other Aortic Aneurysm, Abdominal trials with a reported enrollment target (32% higher). The listed sponsor is W.L.Gore & Associates, which has 53 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Aortic Aneurysm, Abdominal appearing as the primary indexed condition, and to 1 intervention - of which GORE® EXCLUDER® Conformable AAA Endoprosthesis is the first listed.

NCT02489539 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, Minnesota, California.

Frequently Asked Questions

What is clinical trial NCT02489539 about?

NCT02489539 is a clinical study titled "Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms". The purpose of the study is to assess the safety and effectiveness of the GORE® EXCLUDER® Conformable AAA Endoprosthesis to treat an infrarenal aneurysm located in the abdominal aorta. Performance of the GORE® EXCLUDER® Conformable AAA Endoprosthesis will be judged by separate performance goals.

What is the current status of trial NCT02489539?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 175 participants. The study started on 2017-12-19. Estimated completion is 2027-12-31.

What conditions does trial NCT02489539 study?

This clinical trial studies the following conditions: Aortic Aneurysm, Abdominal.

What interventions are being tested in trial NCT02489539?

The interventions under investigation include: GORE® EXCLUDER® Conformable AAA Endoprosthesis (DEVICE).

Who is sponsoring clinical trial NCT02489539?

This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02489539 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aortic Aneurysm, Abdominal

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.